Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
Open Access
- 10 September 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 119 (6), 693-696
- https://doi.org/10.1038/s41416-018-0251-2
Abstract
Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical role in tumourigenesis in 40% of infant HGG. Here we report the first case of a TRK fusion-driven HGG treated with larotrectinib-the first selective pan-TRK inhibitor in clinical development. This 3-year-old girl had failed multiple therapies including chemotherapy and radiotherapy. Tumour profiling confirmed an ETV6-NTRK3 fusion. Treatment with larotrectinib led to rapid clinical improvement with near total resolution of primary and metastatic lesions on MRI imaging. This is the first report of a TRK fusion glioma successfully treated with a TRK inhibitor.This publication has 15 references indexed in Scilit:
- Outcome of young children with high‐grade glioma treated with irradiation‐avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trialsPediatric Blood & Cancer, 2016
- Pediatric high-grade glioma: biologically and clinically in need of new thinkingNeuro-Oncology, 2016
- NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United StatesCancer, 2016
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2015
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Cancer Discovery, 2015
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaNature Genetics, 2014
- The integrated landscape of driver genomic alterations in glioblastomaNature Genetics, 2013
- Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer GroupJournal of Clinical Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Treatment of infants with malignant gliomas: The Pediatric Oncology Group ExperienceJournal of Neuro-Oncology, 1996